| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 03/16/2010 | CA2438646C Pyrimidine derivatives for inhibition of cell-proliferation |
| 03/16/2010 | CA2437718C Carboline derivatives |
| 03/16/2010 | CA2396965C Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| 03/16/2010 | CA2395121C Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method |
| 03/16/2010 | CA2386980C Benzodiazepine derivatives for use in acute or chronic neurological disorders |
| 03/16/2010 | CA2372575C Bradykinin receptor antagonists |
| 03/11/2010 | WO2010028088A2 Sulfur-linked compounds for treating opthalmic diseases and disorders |
| 03/11/2010 | WO2010027838A1 Mir 204, mir 211, their anti-mirs, and therapeutic uses of same |
| 03/11/2010 | WO2010027002A1 Ring-fused morpholine derivative having pi3k-inhibiting activity |
| 03/11/2010 | WO2010025485A1 Use of galanthaminium bromide for producing ophthalmic formulations for treating glaucoma |
| 03/11/2010 | WO2009090453A3 Compositions comprising (r) -verapamil having mt1 receptor activity |
| 03/11/2010 | WO2009080818A3 Guanidine based compounds |
| 03/11/2010 | WO2009071947A3 Potassium ion channel modulators and uses thereof |
| 03/11/2010 | US20100063146 Method for treating disorders related to complement activation |
| 03/11/2010 | US20100063079 Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators |
| 03/11/2010 | US20100063060 Therapeutic agent for glaucoma comprising Rho Kinhase inhibitor and prostaglandin |
| 03/11/2010 | US20100063052 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 03/11/2010 | US20100063035 Carbonic anhydrase inhibitors derivatives |
| 03/11/2010 | US20100063017 Ophthalmic Suspension for Ocular Use |
| 03/11/2010 | US20100062975 Method for the treatment and prevention of ocular disorders |
| 03/11/2010 | US20100062061 Method For Making Cetirizine Tablets |
| 03/11/2010 | CA2736229A1 Sulfur-linked compounds for treating opthalmic diseases and disorders |
| 03/10/2010 | EP2161282A1 Peptide analogues of PACAP |
| 03/10/2010 | EP2161280A2 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications |
| 03/10/2010 | EP2161262A1 THCV and THCV extracts derived from plant material |
| 03/10/2010 | CN101665536A Anti-vegf antibodies |
| 03/10/2010 | CN101664414A Combination of brimonidine and timolol for topical ophthalmic use |
| 03/10/2010 | CN101664388A transnasal transport/immunisation with highly adaptable carriers |
| 03/10/2010 | CN100593544C Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
| 03/09/2010 | US7674921 cloprostenol or latanoprost; topical use; highly crystalline structures that are easy to formulate into ophthalmic solutions; hydrolysis of these analogs releases only the active PGF2 alpha analog free acid, without the production of toxic and irritant small aliphatic alcohol coproducts |
| 03/09/2010 | US7674786 4-phenyl-N-substituted azetidin-2-ones; selective prostaglandin EP2 agonists; glaucoma or ocular hypertension |
| 03/09/2010 | US7674775 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants |
| 03/09/2010 | US7674455 treating a mammal having amyotrophic lateral sclerosis by transducing a motor neuron of the mammal with an insulin-like growth factor I (IGF-1) gene or a glial cell line-derived neurotrophic factor (GDNF) gene; neurodegenerative disorders |
| 03/09/2010 | CA2399813C Indol-3-yl derivatives |
| 03/09/2010 | CA2312842C Taurine derivatives useable in the treatment of ophthalmic disorders |
| 03/04/2010 | WO2010024772A1 Aspartyl protease inhibitors |
| 03/04/2010 | WO2010024258A1 Ring-fused azole derivative having pi3k-inhibiting activity |
| 03/04/2010 | WO2010024227A1 Novel pyrrole derivative having, as substituents, ureide group, aminocarbonyl group and bicyclic group which may have substituent |
| 03/04/2010 | WO2010024110A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| 03/04/2010 | WO2010023705A1 Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders |
| 03/04/2010 | WO2010022725A1 Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
| 03/04/2010 | WO2010006117A3 Cyclosporin derivatives for treating ocular and dermal diseases and conditions |
| 03/04/2010 | WO2009083768A3 Use of partly hydrolyzed fish gelatin for the preparation of topically administered pharmaceutical compositions |
| 03/04/2010 | US20100056631 Antiallergenic composition |
| 03/04/2010 | US20100056547 OPHTHALMIC COMPOSITIONS COMPRISING dDC |
| 03/04/2010 | US20100056528 Sulfonamide derivatives with therapeutic indications |
| 03/04/2010 | US20100056522 Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitor effect as active ingredient |
| 03/04/2010 | US20100056512 Pyrimidine compounds |
| 03/04/2010 | US20100056432 Template-fixed peptidomimetics with antibacterial activity |
| 03/04/2010 | CA2734981A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| 03/04/2010 | CA2734551A1 Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
| 03/04/2010 | CA2733648A1 Novel pyrrole derivative having, as substituents, ureide group, aminocarbonyl group and bicyclic group which may have substituent |
| 03/03/2010 | EP2159226A1 Antihistaminic and antiallergic agent and a method for the production thereof. |
| 03/03/2010 | EP1505973B1 Combinations for treating multiple myeloma |
| 03/03/2010 | EP1162998B1 Vaccine against streptococcus pneumoniae capsular polysaccharides |
| 03/03/2010 | CN101659639A Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 03/02/2010 | US7671252 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | US7671177 Botulinum neurotoxin type E having increased biological half-life for use treatment and prevention of autonomic, neuromuscular and pain disorders |
| 03/02/2010 | US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/02/2010 | US7671074 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others; N-{amino-[pyridin-2-yl-methyl)-amino]-methylene}-4-methylbenzenesulfonamide |
| 03/02/2010 | CA2292836C Prostaglandin pharmaceutical compositions |
| 02/25/2010 | WO2010020981A1 A3 adenosine receptor allosteric modulators |
| 02/25/2010 | WO2010001258A3 Inhibition of tumour growth and metastases |
| 02/25/2010 | WO2009077736A4 A medicament comprising a parasympathetic agonist and a sympathetic antagonist or a sympathetic agonist |
| 02/25/2010 | WO2008144347A8 Combinations comprising a fluoroquinolone for treating, reducing, ameliorating, or preventing infections |
| 02/25/2010 | US20100048705 Methods of treating and preventing neovascularization with omega-3 polyunsaturated fatty acids |
| 02/25/2010 | US20100048669 Therapeutic compounds |
| 02/25/2010 | US20100048626 Aryl Substituted Pyridines and the Use Thereof |
| 02/25/2010 | US20100048608 Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and Diseases |
| 02/25/2010 | US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 02/25/2010 | US20100048551 Tricyclic Compounds Useful as Inhibitors of Kinases |
| 02/25/2010 | US20100048549 Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 |
| 02/25/2010 | US20100048542 Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 02/25/2010 | US20100048522 Ear infections, optionally with antiinflammatory agent |
| 02/25/2010 | US20100047330 Treatment for dark adaptation |
| 02/25/2010 | US20100047236 Antibody variants |
| 02/25/2010 | CA2734896A1 Therapeutic substituted pyrroles |
| 02/24/2010 | EP2157092A1 Remedy for diabetes |
| 02/24/2010 | EP2157082A1 Neurite formation promoter |
| 02/24/2010 | EP2157081A1 Indolinones substituted in six locations, their manufacture and their application as medicine |
| 02/24/2010 | EP2156840A2 Use of mometasone furoate for treating airway passage and lung diseases |
| 02/24/2010 | EP2156834A1 Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| 02/24/2010 | EP2156833A1 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient |
| 02/24/2010 | EP2156824A1 Composition of solifenacin or salt thereof for use in solid formulation |
| 02/24/2010 | EP2155733A1 Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure |
| 02/24/2010 | EP1465631B1 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 02/24/2010 | CN101653603A Peptides and antibodies binding to anionic phospholipids and aminophospholipids and their use in treating disease |
| 02/24/2010 | CN101653354A Noninvasive measurements of chemical substances |
| 02/24/2010 | CN100591359C Lentiviral vector-mediated gene transfer and uses thereof |
| 02/24/2010 | CN100591333C Stable eye lotion containing latanoprost as active ingredient |
| 02/24/2010 | CN100591329C Montelukast granule formulation |
| 02/23/2010 | USRE41151 Comprising a modified NSAID, wherein the NSAID is covalently attached either directly or through a linker molecule to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety; nonsteroidal anti-inflammatory drugs; side-effect reduction |
| 02/23/2010 | USRE41150 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 02/23/2010 | US7667052 Bioactive substance |
| 02/23/2010 | US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 02/23/2010 | US7667007 αvβ3-specific antibodies |
| 02/23/2010 | US7666892 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12 |
| 02/23/2010 | US7666876 Buprenorphine formulations for intranasal delivery |
| 02/23/2010 | US7666867 Heteroindanes: a new class of potent cannabimimetic ligands |